BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targ...
September 25 2019 - 6:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, today announced the addition of immunology expert, Cara L.
Haymaker, Ph.D., to its Scientific Advisory Board, effective
immediately. Additionally, Dr. Bill Williams, BriaCell’s President
& CEO, has been selected to lead the upcoming special joint
issue of the prestigious, peer-reviewed journals, Frontiers in
Pharmacology and Frontiers in Oncology with the research topic of
'Targeted Immunotherapy for Cancer'.
Dr. Cara Haymaker is an assistant professor at
Department of Translational Molecular Pathology, Division of
Pathology/Lab Medicine at The University of Texas MD Anderson
Cancer Center. She has been appointed as Director, CCSG Oncology
Research and Immunomonitoring Core, Department of Translational
Molecular Pathology, Division of Pathology and Lab Medicine since
2018, and as Faculty Member, Translational Molecular Pathology
Immunoprofiling Laboratory (TMP-IL) since 2016 at MD Anderson. Dr.
Haymaker’s research has focused on Tumor-infiltrating Lymphocytes
and their Immunologic Characteristics in solid tumors. Dr. Haymaker
earned a Ph.D. in immunology from University of Missouri, Columbia,
MO, and has completed her Postdoctoral Fellowship at MD Anderson.
She has authored 45 peer-reviewed original research articles.
“We are thrilled to welcome Cara to BriaCell’s
Scientific Advisory Board," said Dr. Bill Williams. "Cara brings
expertise in a wide array of areas, including in immuno-oncology,
cancer biomarkers, protein design, personalized diagnostics, and
engineering of targeted immunotherapies, to help guide BriaCell in
the development of potent, targeted immunotherapies for advanced
breast cancer patients with limited therapeutic options. We look
forward to further utilizing Cara’s extensive experience as our
novel personalized off-the-shelf immunotherapy heads into clinical
trials.”
‘Targeted Immunotherapy for
Cancer’
Separately, the prestigious, peer-reviewed
journal, Frontiers in Pharmacology, has selected Dr. Bill Williams
as a leading expert in immunotherapy for cancer and in clinical
pharmacology to coordinate an upcoming special issue. Dr. Williams
has selected the research topic of 'Targeted Immunotherapy for
Cancer'. Both Frontiers in Pharmacology and Frontiers in
Oncology will be participating in this special issue. Information
on the special issue can be found at
https://www.frontiersin.org/research-topics/11611/targeted-immunotherapy-for-cancer.
About Frontiers Journals
About Frontiers: With a vision
to make science open and peer-review rigorous, transparent and
efficient, Frontiers has been supported by hundreds of thousands of
researchers to become one of the most-cited, largest and
fastest-growing Open Access Publishers and Open Science
Platforms.
During the past 15 years, dramatic progresses
have been made in the field of cancer immunity and immunotherapy.
The clinical impact associated anti-tumor immunity, the impressive
clinical activities of monoclonal antibodies modulating the immune
microenvironment or directed to tumor cells, the successes of
engineered T cells therapies and the development of targeted
immunotherapies against mutated tumor antigens demonstrate that the
immune system can be a powerful ally against cancer.
The pharmacology of targeted immunotherapies
relies on their ability to induce a cancer-specific immune
response. The goal of the Frontiers in Pharmacology
publication is to drive the rapidly moving field of
immunosurveillance, tumor escape and immunotherapy by hosting
primary research, discussions, reviews, conflicting positions and
novel hypotheses. For additional information on the Frontiers in
Pharmacology journal, please visit:
https://www.frontiersin.org/journals/pharmacology/sections/pharmacology-of-anti-cancer-drugs.
Frontiers in Oncology publishes rigorously
peer-reviewed research across the entire field of cancer research.
For more information on the Frontiers in Oncology journal, please
visit: https://www.frontiersin.org/journals/oncology.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology
company developing targeted and safe approaches for the management
of cancer.
BriaCell is currently conducting a Phase
I/IIa clinical trial of Bria-IMT™, BriaCell’s lead
candidate, in a Combination Study with immune checkpoint inhibitors
such as pembrolizumab [KEYTRUDA®; manufactured by Merck & Co.,
Inc. (NYSE: MRK)]. The Combination Study is listed in
ClinicalTrials.gov as NCT03328026.
BriaCell also has a non-exclusive clinical trial
collaboration with Incyte Corporation to evaluate the effects of
combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations
of compounds from Incyte’s development portfolio with Bria-IMT™ in
advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an off-the-shelf
personalized immunotherapy, for advanced breast cancer. Bria-OTS™
immunotherapy treatments are personalized to match the patient
without the need for personalized manufacturing. Bria-OTS™, which
is expected to cover over 99 percent of the patient population, is
designed to produce a potent and selective immune response against
the cancer of each patient while eliminating the time, expense and
complex manufacturing logistics associated with other personalized
immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Sep 2023 to Sep 2024